Home › Obsessive-Compulsive Disorder › NCT05224414
Interpretation Bias as a Mechanism of Treatment Response in OCD
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * 1\) OCD Institute patients * 2\) adults (\> 18 years old) * 3\) able to complete a computer task for 20 minutes * 4\) consent to main OCD Institute study protocol * 5\) primary diagnosis of OCD (as measured by a score of \>16 on the Y-BOCS and a clinical diagnosis of OCD by their treatment team * 6\) score of \>131 on the Obsessive Beliefs Questionnaire-44 at admission \[which is 1 SD above the mean score of the non-clinical sample reported in the original validation paper by the Obsessive Compulsive Cognitions Working Group (2005)\] Exclusion Criteria: * 1\) Currently experiencing acute symptoms of psychosis * 2\) Psychotic disorder diagnosis
About the study
This study will conduct a randomized controlled trial of Cognitive Bias Modification for Interpretation (CBM-I) as an augmentation to treatment as usual for obsessive compulsive disorder (OCD). CBM-I is a digital intervention designed to directly manipulate interpretation bias through repeated practice on a training task, thereby inducing cognitive changes in a relatively automatic or implicit manner. Specifically, this study will examine the feasibility, acceptability, and clinical outcomes associated with CBM-I.
Adults with obsessive compulsive disorder (OCD) will be recruited from a treatment program for this disorder and participants will be randomly assigned to either receive: 1) up to 12 sessions of CBM-I, or or up to 12 sessions of psychoeducation as a control condition.
What is being tested
- Cognitive bias modification for interpretation bias (behavioral)
- Psychoeducation (behavioral)
Sponsor: Mclean Hospital · Participants: 106 · Started: Mar 30, 2022
Contact the study team
- Martha Falkenstein, PhD · Phone: 617-855-4424
Official record on ClinicalTrials.gov — NCT05224414
Locations in the U.S.
| Massachusetts | McLean Hospital, Belmont |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.